首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas
【24h】

Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas

机译:结膜黑色素瘤带有BRAF和NRAS突变,其拷贝数变化与皮肤和粘膜黑色素瘤相似

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Conjunctival melanoma is a rare but potentially deadly tumor of the eye. Despite effective local therapies, recurrence and metastasis remain frequent. Once the tumor has metastasized, treatment options are limited and the prognosis is poor. To date, little is known of the genetic alterations in conjunctival melanomas. Experimental Design: We conducted genetic analysis of 78 conjunctival melanomas, to our knowledge the largest cohort reported to date. An oncogene hotspot array was run on 38 samples, screening for a panel of known cancer-relevant mutations. Thirty tumors were analyzed for genome-wide copy number alterations (CNA) using array-based comparative genomic hybridization. Sanger sequencing of selected target mutations was conducted in all samples. Results: BRAF mutations were identified in 23 of 78 (29%) tumors. NRAS mutations, previously not recognized as relevant in conjunctival melanoma, were detected in 14 of 78 (18%) tumors. We found CNAs affecting various chromosomes distributed across the genome in a pattern reminiscent of cutaneous and mucosal melanoma but differing markedly from uveal melanoma. Conclusions: The presence of NRAS or BRAF mutations in a mutually exclusive pattern in roughly half (47%) of conjunctival melanomas and the pattern of CNAs argue for conjunctival melanoma being closely related to cutaneous and mucosal melanoma but entirely distinct from uveal melanoma. Patients with metastatic conjunctival melanoma should be considered for therapeutic modalities available for metastatic cutaneous and mucosal melanoma including clinical trials of novel agents.
机译:目的:结膜黑色素瘤是一种罕见但可能致命的眼部肿瘤。尽管有有效的局部疗法,但复发和转移仍很频繁。一旦肿瘤转移,治疗选择就受到限制并且预后很差。迄今为止,关于结膜黑色素瘤的遗传改变知之甚少。实验设计:我们对78例结膜黑色素瘤进行了遗传分析,据我们所知,这是迄今为止报道的最大的队列研究。癌基因热点阵列在38个样品上运行,筛选出一组已知的癌症相关突变。使用基于阵列的比较基因组杂交技术分析了30个肿瘤的全基因组拷贝数变化(CNA)。在所有样品中对选择的靶突变进行Sanger测序。结果:在78例肿瘤中有23例(29%)发现了BRAF突变。在78个肿瘤中,有14个(18%)肿瘤中检出了NRAS突变,以前在结膜黑色素瘤中不被认为是相关的。我们发现CNA影响着分布在基因组上的各种染色体,其模式让人联想到皮肤和粘膜黑色素瘤,但与葡萄膜黑色素瘤明显不同。结论:在大约一半(47%)的结膜黑色素瘤中,NRAS或BRAF突变以互斥方式存在,而CNA的形态则说明结膜黑色素瘤与皮肤和粘膜黑色素瘤密切相关,但与葡萄膜黑色素瘤完全不同。转移性结膜黑色素瘤患者应考虑可用于转移性皮肤和粘膜黑色素瘤的治疗方式,包括新型药物的临床试验。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号